These findings indicate that CUDC-907 may have a role in the treatment of Myc-expressing DLBCL and ABC-DLBCL, which are known to have a poor outcome when treated with standard combination chemotherapy [22]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.